"methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 28, Issue 2, 2014, Pages

  Evora, Paulo R B ^a   José Rodrigues, Alfredo ^a   Celotto, Andrea C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; METHYLENE BLUE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

CLINICAL PRACTICE; DOWN REGULATION; DRUG USE; ENZYME ACTIVITY; HUMAN; LETTER; MORTALITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHOCK; UPREGULATION; VASOPLEGIA; ANAPHYLAXIS; CHEMOLUMINESCENCE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RISK BENEFIT ANALYSIS; SEPSIS; TREATMENT RESPONSE;

ANTIDOTES; FEMALE; HUMANS; MALE; METHYLENE BLUE; VASOPLEGIA;

EID: 84896400944     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2013.09.009     Document Type: Letter

References (9)

1. M.M. Weiner, H.M. Lin, and D. Danforth et al. Methylene blue is associated with poor outcomes in vasoplegic shock J Cardiothorac Vasc Anesth 27 2013 1233 1238
2. D.H. Jang, L.S. Nelson, and R.S. Hoffman Methylene blue for distributive shock: A potential new use of an old antidote J Med Toxicol 9 2013 242 249
3. W.J. Gomes, A.C. Carvalho, and J.H. Palma et al. Vasoplegic syndrome: A new dilemma J Thorac Cardiovasc Surg 107 1994 942 943
4. P.R. Evora, P.J. Ribeiro, and J.C. de Andrade Methylene blue administration in SIRS after cardiac operations Ann Thorac Surg 63 1997 1212 1213
5. P.R. Evora Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J Thorac Cardiovasc Surg 119 2000 632 634
6. P.R. Evora, P.J. Ribeiro, and W.V. Vicente et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: Fifteen years of questions, answers, doubts and certainties Rev Bras Cir Cardiovasc 24 2009 279 288
7. S.N. Blacker, and F.X. Whalen Vasoplegic syndrome: Does the timing of methylene blue matter? J Anesth Clinic Res 4 2013 333
8. D. Fernandes, J.E. da Silva-Santos, and D. Duma et al. Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity Mol Pharmacol 69 2006 983 990
9. F. Viaro, C.F. Baldo, and V.K. Capellini et al. Plasma nitrate/nitrite (NOx) is not a useful biomarker to predict inherent cardiopulmonary bypass inflammatory response J Card Surg 23 2008 336 338